Loading…
NKTR
Nektar Therapeutics
NASDAQ· Healthcare· Biotechnology· CUSIP 640268306
$38.65+0.99%Price as of Oct 23, 00:47 UTC · updated once a day, after the close
At a glance
Nektar Therapeutics (NKTR) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in San Francisco, United States and has 63 employees. The company is worth $1.32B. Revenue was $55.23M in fiscal 2025, down 43.9% from the year before. It reported a net loss of $164.08M. The share price is 64.5% below its 52-week high of $109.00. 4 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Two Sigma (Two Sigma Investments), at $83.91M. In that quarter, 3 of them opened or added to the position and 1 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Key metrics
- Market cap
- $1.32B
- P/E
- —
- Forward P/E
- —
- P/B
- 1.5x
- Dividend yield
- 0.00%
- Payout
- —
- EPS
- -$18.96
- ROE
- -35.76%
- Profit margin
- -287.84%
- Revenue growth
- -9.30%
- Beta
- 1.27
- 52-week high
- $109.00
- 52-week low
- $33.40
History
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -78.8% over 5Y.
today you would have $157.34▼ -84.3%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 17 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $42.28 | $13.95 | $8.40 | $33.90 | $202.65 | $255.00 | $323.85 | $493.05 | $895.80 | $184.05 | $252.75 | $232.50 | $170.25 | $111.15 | $84.00 | $192.75 | $139.80 | |
| P/E |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| RAPPRapport Therapeutics, Inc. | $27.57 | — | 3.1x | 0.00% | -39.96% | $1.32B |
| USPHU S Physical Therapy Inc | $88.73 | 467.0x | 3.0x | 2.07% | 6.51% | $1.32B |
| TSHATaysha Gene Therapies, Inc. | $4.01 | — | 3.4x | 0.00% | -47.05% | $1.3B |
| NUTXNutex Health Inc. | $186.10 |
About the company
- 63
- San Francisco, United States